about
Systemic antifungal drugs for invasive fungal infection in preterm infantsHow to manage aspergillosis in non-neutropenic intensive care unit patientsChemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative.Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin BNanodisks derived from amphotericin B lipid complex.It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drugSurgery of pulmonary aspergillomas in immunocompromised patients.Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatusThe production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations.Systemic antifungal therapy: new options, new challenges.Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.Nanosuspensions: a promising drug delivery strategy.Apoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin B.Retrospective Analysis on the Use of Amphotericin B Lipid Complex in Neutropenic Cancer Patients with Suspected Fungal Infections in Lebanon, a Single Center Experience and Review of International Guidelines.Liposomal amphotericin B as a treatment for human leishmaniasisAntibiotics and antifungals in neonatal intensive care units: a review.Invasive mold infections: recent advances in management approaches.Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity.An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB).Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.Metallic nanoparticles and their medicinal potential. Part II: aluminosilicates, nanobiomagnets, quantum dots and cochleates.A critical appraisal of microemulsions for drug delivery: part II.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Acute kidney injury induced by antimicrobial agents in the elderly: awareness and mitigation strategies.Emulsomes meet S-layer proteins: an emerging targeted drug delivery system.Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.Clinical pharmacokinetics of inhaled antimicrobials.AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules.Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactanReal-time treatment guidelines: considerations during the Exserohilum rostratum outbreak in the United States.Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies.Distinct cytokine release profiles from human endothelial and THP-1 macrophage-like cells exposed to different amphotericin B formulations.
P2860
Q24247376-623E14BB-6264-43EF-9DC1-BDE231F89294Q26999448-7109BF23-9ABC-4850-A3E5-C06830FFF877Q33200348-FDBEF503-3473-4B2D-986E-A2094FF441BFQ33722067-E13D7F59-7C2D-423F-BADD-F356349C3FD9Q33946918-72D325A0-2BFB-4D8B-8809-2D2FE9FC864CQ34302880-D7820760-19D0-4C3F-A7A3-2F7A2C507136Q34443862-50088CC6-7ADC-4A6B-BF25-81A83A755AEAQ34509692-89D1A355-5599-455E-A419-3D0B8D0F0D74Q34596780-E61BA1B4-0AC5-47AC-AA7F-FED3A0782DE4Q34763371-A4D8CAB5-D337-4925-AEB8-CD8E332F6880Q35168703-6C29D43A-E8AE-4316-BD7B-DFD789631B22Q35547641-DE66330C-A8FE-454B-A517-CDF6DB2C68BDQ35585219-8254C17A-CAB9-47C6-B3DE-571A547B8533Q35715408-9A5A71F3-E0EA-4D09-B36E-A407FC22F185Q35826447-574F6094-8BDE-4866-A973-7472E0A3C711Q36272948-2C4F9E5E-CEA3-4B54-9A72-A4DCAB9DA05EQ36427453-AD32023D-D0BB-49EB-BD5A-D241D4CAB4C0Q36456032-DDA00E75-E151-46A3-AB1D-16203807DD65Q36740036-64D04FDC-AD3F-4FC5-BCB5-30D870ADA800Q37428946-EF8A9021-9E8E-4024-8ED5-A5F47C74AC1BQ37684378-D5596AE7-F6FF-4A17-8ADD-5830BB42DB10Q37807907-AABAB2CF-8FCD-4828-804F-F21981D98E23Q37918556-62EAED7B-0824-459A-95B4-A23004E40F4AQ37999793-16B3640B-1673-45CF-A896-FB480A058301Q38136245-BC73E528-D062-47CB-BE27-B52B3FC52A30Q38171567-04467050-F854-4E64-84A3-1E4138632DC2Q38193337-B0357D8A-103B-4C70-99AC-85103CF20F78Q38285837-47F0F383-21F8-4983-9BAB-FEDA987FB594Q38361935-EBC18170-4769-4AC2-9FEB-7D10E2D59AE2Q38363105-F0BF389D-0FDC-4F66-90D1-ED6D37D981FDQ38367260-C0E84627-9C12-45D9-8BDE-CA0A7AD4B5D6Q38872275-30C830ED-4FCC-4120-ACB2-D0C41644E1FAQ39203200-EE440CBC-674C-4767-9791-DC437BCC3274Q39294022-D8176D7E-95DD-477E-98B0-143D50F59952Q39766609-AC8E0FF7-1EA9-41AA-98CF-F45F364F47B7Q39913385-90DD422B-F58B-40FB-B9BA-A80E6F584802Q39955259-DAF41644-EFFF-422E-845F-0C23E866A971Q40166247-26EF50A2-C870-4136-B9A9-7D27835A5A52Q40384862-ACBEFEAE-1138-45E1-8406-F516F9737D03Q40440168-C41DF754-8856-4273-B7E4-4B78C0231A2F
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Overview of the lipid formulations of amphotericin B.
@ast
Overview of the lipid formulations of amphotericin B.
@en
Overview of the lipid formulations of amphotericin B.
@nl
type
label
Overview of the lipid formulations of amphotericin B.
@ast
Overview of the lipid formulations of amphotericin B.
@en
Overview of the lipid formulations of amphotericin B.
@nl
prefLabel
Overview of the lipid formulations of amphotericin B.
@ast
Overview of the lipid formulations of amphotericin B.
@en
Overview of the lipid formulations of amphotericin B.
@nl
P356
P1476
Overview of the lipid formulations of amphotericin B.
@en
P2093
Bertrand Dupont
P356
10.1093/JAC/49.SUPPL_1.31
P407
P478
49 Suppl 1
P577
2002-02-01T00:00:00Z